์ฅ์ฌ์ค๋ฆฐ
์ฅ์ฌ์ค๋ฆฐ์ ์ข์ ์คํํธ๋ผ์ **๋ฒ ํ๋ฝํ๋ง์ ๋ด์ฑ(ํญํฌ๋์๊ตฌ๊ท ) ํ๋์ค๋ฆฐ**์ ๋๋ค. * **์์์ ์ ์ฉ์ฑ**: ์ฃผ๋ก ํ๋์ค๋ฆฌ๋์ ๋ฅผ ์์ฑํ๋ ํฌ๋์๊ตฌ๊ท (์: MSSA, MSSP)์ ์ํ ๋ผ, ํผ๋ถ ๋ฐ ์ฐ์กฐ์ง ๊ฐ์ผ ์น๋ฃ์ ์ฌ์ฉ๋ฉ๋๋ค. * **ํญ๊ท ์คํํธ๋ผ**: ๊ทธ๋ ์์ฑ ๊ตฌ๊ท ์ ๋งค์ฐ ํจ๊ณผ์ ์ ๋๋ค. ๋ฆฌ์ผ์ฐจ, ๋ง์ด์ฝ๋ฐํ ๋ฆฌ์, ์ง๊ท , ๋ง์ด์ฝํ๋ผ์ค๋ง, ๋ฐ์ด๋ฌ์ค ๋ฐ ๋๋ถ๋ถ์ ๊ทธ๋ ์์ฑ๊ท ์๋ ํจ๊ณผ๊ฐ ์์ต๋๋ค. * **๋ด์ฑ ๋ฐฐ๊ฒฝ**: ํฌ๋์๊ตฌ๊ท ์ ๋ฒ ํ๋ฝํ๋ง์ ์๋ ๋ด์ฑ์ ๊ฐ์ง์ง๋ง, **๋ฉํฐ์ค๋ฆฐ ๋ด์ฑ ํฉ์ํฌ๋์๊ตฌ๊ท (MRSA)**์ด๋ **๋ฉํฐ์ค๋ฆฐ ๋ด์ฑ ์์ค๊ฐํฌ๋์๊ตฌ๊ท (MRSP)**์๋ ํจ๊ณผ๊ฐ ์์ต๋๋ค(์ด๋ค์ *mecA* ์ ์ ์๋ฅผ ํตํ ํ์ ๋ถ์ ๋ณํ์ด๋ผ๋ ๋ค๋ฅธ ๋ด์ฑ ๊ธฐ์ ์ ๊ฐ์ง). * **์์ํ์ ํ๊ณ**: ๋ฐ๊ฐ๊ธฐ๊ฐ ๋งค์ฐ ์งง์(6-8์๊ฐ๋ง๋ค ํฌ์ฌ ํ์) ๊ฒฝ๊ตฌ ์์ฒด์ด์ฉ๋ฅ ์ด ๋ฎ๊ณ , ํธ๋ฆฌํ ๋๋ฌผ์ฉ ๊ฒฝ๊ตฌ ์ ํ์ด ๋ถ์กฑํ์ฌ ํ์ฌ ์์ํ์์๋ ๋๋ฌผ๊ฒ ์ฌ์ฉ๋ฉ๋๋ค. ํธ์์ฑ์ ์ํด ์ธํ๋ก์คํฌ๋ฆฐ์ด๋ ์๋ชฉ์์ค๋ฆฐ-ํด๋ผ๋ถ๋์ฐ์ด ๋ ์์ฃผ ์ ํธ๋ฉ๋๋ค.
์์ฉ ๊ธฐ์ : Oxacillin is a **bactericidal beta-lactam antibiotic**. * **Mechanism**: It covalently binds to **Penicillin-Binding Proteins (PBPs)** (specifically transpeptidases) located on the inner membrane of the bacterial cell wall. * **Pathway**: PBP binding โ inhibition of the terminal transpeptidation step of peptidoglycan synthesis โ weakened cell wall โ osmotic instability โ **cell lysis and death**. * **Enzyme Resistance**: The drug features a bulky isoxazolyl side chain that provides steric hindrance, preventing staphylococcal **beta-lactamase (penicillinase)** from hydrolyzing and destroying the beta-lactam ring.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Susceptible infections ยท 22-40 mg/kg PO, SC, IM, or IV q8h ยท PO, SC, IM, IV ยท q8h
- Susceptible infections ยท 20-30 mg/kg IV q6-8h ยท IV ยท q6-8h ยท Dose extrapolated from adult horse data; use lower dose or longer interval in premature foals or those less than 7 days old.
- Susceptible infections ยท 25-50 mg/kg IM, IV twice daily ยท IM, IV ยท q12h
- Susceptible infections ยท 22-40 mg/kg PO, SC, IM, or IV q8h ยท PO, SC, IM, IV ยท q8h
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity to penicillins
- Oral administration in patients with septicemia, shock, or other grave illnesses (due to delayed/diminished GI absorption)
์ด์๋ฐ์
- Anorexia
- Vomiting
- Diarrhea
- Antibiotic-associated diarrhea and superinfections
- Hypersensitivity reactions (rash, fever, eosinophilia, anaphylaxis)
- Neurotoxicity (ataxia, CNS effects at very high doses)
- Elevated liver enzymes
- Tachypnea
- Dyspnea
- Edema
- Tachycardia
์ฝ๋ฌผ ์ํธ์์ฉ
- Aminoglycosides ยท In vitro evidence of synergism against S. aureus strains; however, mixing in the same syringe/fluid line can cause physical inactivation.
- Cyclosporine ยท Oxacillin may reduce cyclosporine serum levels.
- Probenecid ยท Competitively blocks the tubular secretion of oxacillin, thereby increasing serum levels and prolonging serum half-life.
- Tetracyclines ยท Theoretical antagonism (bacteriostatic drugs may interfere with bactericidal action of penicillins); concurrent use is usually not recommended.
- Warfarin ยท Oxacillin may cause decreased warfarin efficacy.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (resolution of infection)
- Signs of adverse effects (GI upset, allergic reactions)
๊ณผ์ฉ๋
Acute oral overdoses are unlikely to cause significant problems other than **gastrointestinal distress** (vomiting, diarrhea). In humans, very high dosages of parenteral penicillins, especially in patients with compromised renal function, have induced **CNS effects and neurotoxicity**.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.